Company profile
Crucible Therapeutics Limited is a UK company with status active founded in 2023.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AP01 | Transaction MzQ0MjUwMTI2NWFkaXF6a2N4
Published 11 Nov 2024 12:55
TM01 | Transaction MzQ0MjUwMTE2MmFkaXF6a2N4
Published 13 Nov 2024 09:30
AA | Transaction MzQ0MDA2MjI3NWFkaXF6a2N4 | Paper/PDF filed
Published 19 Oct 2024 06:23
Company registered at Companies House
Crucible Therapeutics develops gene therapy to treat neurodegenerative diseases.
The company is sponsoring research contracts for two post-doctoral researchers at the University of Sheffield and outsource reagents and research from various CDMOs internationnally. It is currently operating at pre-clinical level.
Young company established in September 2023
